Evaluation of the Use of Guaco Syrup for Dilation and Reduction of Inflammation in the Respiratory Tract Through Pulmonary Function Tests in Asthmatic Volunteers
- Conditions
- AsthmaC08.127.108
- Registration Number
- RBR-4n26tf
- Lead Sponsor
- niversidade federal do paraná
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Moderate persistent asthm (according to the classification criteria included in the IV Brazilian Guidelines for Asthma Management); aged between 18 and 60 years; diagnosis of asthma performed by spirometry (FEV1 / FVC <90%, with FEV1 being forced expiratory volume in 1 second and FVC functional vital capacity).
Volunteers who had a stroke or acute myocardial infarction in the last three months; aortic aneurysm; systolic blood pressure higher than 200 mmHg or diastolic blood pressure higher than 90 mmHg; epileptics; unable to understand the procedure and implications of the study; with induced bronchoconstriction by recent spirometry; recent airway infection (during the last six weeks); during or near an asthma exacerbation; pregnant or breastfeeding women; in use of cholinesterase inhibitors; and smokers.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bronchodilator Activity<br>Positive bronchodilator response verified by spirometry test. Elevation of FEV1 in 200 ml or more and, in parallel, increase in FEV1 by 12% when compared to baseline or 7% when compared to the value predicted for the volunteer.<br><br>Anti-inflammatory activity<br>Positive anti-inflammatory response evaluated by spirometry test. After the intervention, the increase in methacholine dose required to cause a 20% decrease in FEV 1 values characterizes the anti-inflammatory effect.
- Secondary Outcome Measures
Name Time Method We don't expect secondary outcomes.